Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism

Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study

(2015) Nobuya Inagaki et al.   Lancet Diabetes & Endocrinology

DPP-4 inhibitors: pharmacological differences and their clinical implications

(2014) Antonio Ceriello et al.   Expert Opinion On Drug Safety

SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial

(2013) Nobuya Inagaki et al.   Lancet Diabetes & Endocrinology

Design and Synthesis of Pyrimidinone and Pyrimidinedione Inhibitors of Dipeptidyl Peptidase IV

(2010) Zhiyuan Zhang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP8/9 inhibitor

(2009) Jia-Jing Wu et al.   BIOCHEMICAL PHARMACOLOGY

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

(2008) P COVINGTON et al.   CLINICAL THERAPEUTICS

Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited

(2008) B. F. Burkey et al.   DIABETES OBESITY & METABOLISM

Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys

(2008) Bumsup Lee et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation

(2008) William J. Metzler et al.   PROTEIN SCIENCE